Illumina (ILMN) Secures $2,989.55 Reimbursement for TruSight Oncology Test
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 20 2026
0mins
Source: NASDAQ.COM
- Reimbursement Approval: Illumina's TruSight Oncology Comprehensive test has received CMS approval for reimbursement at $2,989.55 per test, significantly enhancing patient access to comprehensive genomic profiling and advancing precision oncology.
- Implementation Timeline: The reimbursement will take effect on January 1, 2026, under the Clinical Laboratory Fee Schedule using Proprietary Laboratory Analysis code 0543U, providing greater financial support for healthcare providers.
- Market Reaction: Although Illumina's current stock price is $137.00, down 3.24% on Nasdaq, the reimbursement news may improve investor confidence in the medium to long term, potentially driving a stock price recovery.
- Strategic Implications: By securing reimbursement, Illumina not only strengthens its competitive position in the precision medicine sector but also lays the groundwork for future product innovation and market expansion, aligning with the growing demand for genomics in healthcare.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ILMN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ILMN
Wall Street analysts forecast ILMN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ILMN is 124.12 USD with a low forecast of 40.50 USD and a high forecast of 195.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
4 Buy
6 Hold
3 Sell
Hold
Current: 152.090
Low
40.50
Averages
124.12
High
195.00
Current: 152.090
Low
40.50
Averages
124.12
High
195.00
About ILMN
Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ark Invest Unveils 2026 Big Ideas, Forecasts 1.9% GDP Growth Boost
- Technological Acceleration: Ark Invest's report highlights that capital investment in disruptive innovation platforms could contribute 1.9 percentage points to annualized real GDP growth during this decade, emphasizing the potential of technologies like robotaxis and next-gen data centers.
- Strong ETF Performance: In 2025, Ark's Autonomous Technology & Robotics ETF and Space & Defense Innovation ETF achieved returns of 49.8% and 49.2%, respectively, showcasing the firm's ability to generate returns in emerging technology sectors.
- Bitcoin Holdings Surge: The report indicates that U.S. ETFs and public companies now hold 12% of total Bitcoin supply, with Bitcoin ETF balances up 19.7% and public company Bitcoin holdings up 73% in 2025, reflecting strong market demand for digital assets.
- Diverse Investment Opportunities: Ark Invest identifies several publicly traded companies, including Coinbase, Illumina, and Waymo, as key investment opportunities for the 2026 themes, indicating the firm's forward-looking approach to diversified investment strategies.
Continue Reading
Illumina Secures CMS Reimbursement for TruSight Oncology Test at $2,989.55
- Reimbursement Impact: Illumina's TruSight Oncology Comprehensive test has secured CMS reimbursement at $2,989.55 per test, effective January 1, 2026, which is expected to significantly enhance the adoption of this test in the U.S. healthcare system, thereby increasing the company's market share in precision oncology.
- Genomic Testing Advantage: The test assesses over 500 genes to provide clinically actionable results for treatment decisions, anticipated to enable more laboratories to deliver precision oncology diagnostics, addressing the growing market demand.
- Stock Performance: Illumina shares are currently priced at $145.22, trading 2.65% above the 12-month moving average, reflecting a positive market trend with a 2.9% increase over the past year, indicating investor confidence in the company's future growth potential.
- Analyst Ratings: Despite a premium P/E ratio of 31.8x indicating high valuation, analysts expect a 28% earnings growth to justify this valuation, with recent target price increases from firms like TD Cowen and Guggenheim reflecting optimistic market sentiment towards Illumina.
Continue Reading